Cocrystal Pharma Announces Stock Offering and Warrant Placement

Cocrystal Pharma ( (COCP) ) just unveiled an update.

On September 12, 2025, Cocrystal Pharma announced the pricing of a registered direct offering of common stock and a concurrent private placement of warrants, expected to close around September 15, 2025. The offering, managed by H.C. Wainwright & Co., is anticipated to generate approximately $4.7 million upfront, with potential additional proceeds of $8.3 million from warrant exercises. The funds are intended for working capital and general corporate purposes, impacting the company’s financial strategy and market operations.

The most recent analyst rating on (COCP) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Cocrystal Pharma stock, see the COCP Stock Forecast page.

Spark’s Take on COCP Stock

According to Spark, TipRanks’ AI Analyst, COCP is a Underperform.

Cocrystal Pharma faces significant financial challenges, with no revenue and ongoing operational losses severely affecting its stock score. The technical analysis indicates potential downward pressure, while the negative valuation metrics are concerning. However, recent corporate events provide some positive aspects, suggesting future growth potential. Overall, the company’s stock score reflects these mixed factors, indicating substantial risk with some long-term opportunities.

To see Spark’s full report on COCP stock, click here.

More about Cocrystal Pharma

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on developing innovative antiviral treatments for diseases such as influenza, viral gastroenteritis, COVID, and hepatitis. The company utilizes unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.

Average Trading Volume: 76,681

Technical Sentiment Signal: Sell

Current Market Cap: $14.77M

For a thorough assessment of COCP stock, go to TipRanks’ Stock Analysis page.